IL17B and neoplasm: Recent studies have provided evidence that IL-17B binds to its receptor to promote the antiapoptosis, tumorigenesis and the resistance to paclitaxel in breast cancer [6, 36] and to facilitate invasion, vasculogenic endothelial cell and macrophage recruitment to promote pancreatic cancer cell survival, enhancing tumor malignancy [7].